Remuneration, KPI's, STI's, LTI's, page-2

With regard to your concerns about commercialising the science, it appears the guy below should have a good handle on it.

Obviously there are valid concerns around Vivagel and Viraleze, particularly clarity around the lack of timely success with regulatory authorities and / or the strategy of partnering / getting sales into key markets.

- but could you outline your concerns around the DEP drug (cancer) portfolio status?




Tony Eglezos, BSc (Hons), PhD, MBAVice President, Business Development Starpharma

Dr Eglezos has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australasia.Most recently he was Director Commercial Operations, Pharmaceuticals and In-Licensing at bioCSL and, prior to that, Senior Director Business Development and Licensing at CSL.During his 7 years in business development with CSL, Tony’s responsibilities included acquisitions and due-diligence, commercialisation of in-licensed pharmaceutical products and out-licensing of IP for partnered development for the global R&D group. Tony has a PhD in Immunology from the University of Melbourne and an MBA from the University of Technology Sydney.

LinkedIn - Recommendation:

“While launching the Blockbuster Drug Humira in Spain, I worked very closely with Tony as we shared responsibilities being both members of the strategic International launch team. With his clear national and International business vision, Tony's input was critical to achieve one of the company's most successful launch. Furthermore, Tony is a real team player, always willing and prepared to provide support and therefore inspires strong leadership.”